LS
NVAX icon

Livforsakringsbolaget Skandia’s Novavax NVAX Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,100
Closed -$20K – 592
2022
Q3 		$20K Hold
1,100
– – ﹤0.01% 463
2022
Q2 		$57K Sell
1,100
-1,100
-50% -$57K 0.01% 532
2022
Q1 		$162K Hold
2,200
– – 0.01% 501
2021
Q4 		$314K Hold
2,200
– – 0.02% 387
2021
Q3 		$456K Hold
2,200
– – 0.03% 355
2021
Q2 		$468K Buy
2,200
+1,100
+100% +$202K 0.03% 361
2021
Q1 		$199K Buy
+1,100
New +$219K 0.01% 468

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIG
Herr Investment Group Austin, Texas $1.5B AUM 29.27% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Livforsakringsbolaget Skandia's NVAX Position: Q4 2022 in Review

Livforsakringsbolaget Skandia sold out of Novavax (NVAX) in Q4 2022, closing a stake of 1,100 shares — an estimated $20K sold.

Livforsakringsbolaget Skandia first reported a position in NVAX in Q1 2021 and held it in 7 quarters. The position peaked at $468K in Q2 2021. 253 funds tracked by Wall St. Rank hold NVAX as of Q4 2022.

  • Livforsakringsbolaget Skandia reported no remaining Novavax position as of Q4 2022 after selling out during the quarter.
  • Livforsakringsbolaget Skandia sold 1,100 Novavax shares in Q4 2022, an estimated $20K.
  • Livforsakringsbolaget Skandia first reported a position in Novavax in Q1 2021 and held it in 7 quarters.
  • Livforsakringsbolaget Skandia's Novavax position peaked at $468K in Q2 2021.
  • 253 funds tracked by Wall St. Rank held Novavax as of Q4 2022.

Based on Livforsakringsbolaget Skandia's 13F filing for Q4 2022, filed 13 Feb 2023.